Analysis of U.S. Patent 4,647,447: Scope, Claims, and Patent Landscape
What Are the Key Aspects of U.S. Patent 4,647,447?
U.S. Patent 4,647,447, issued on March 3, 1987, pertains to a novel antidepressant compound. The patent claims cover a specific chemical structure, related derivatives, and their use in treating depression. The patent is assigned to Eli Lilly and Company. It has a crucial influence on the antidepressant patent landscape, especially within the serotonin reuptake inhibitor (SRI) class.
What is the Scope of Patent 4,647,447?
The patent claims a class of compounds characterized by a core chemical structure, with various substituents defining its derivatives. Its scope includes:
- The chemical formula: a phenylpiperazine derivative with specific substitutions on the aromatic ring and the piperazine moiety.
- Pharmaceutical compositions comprising the compound.
- Methods for treating depression using the compound.
- Specific synthetic routes for preparing the compound.
The core structure consists of a phenylpiperazine, where the phenyl ring is substituted with groups such as halogens, alkyls, or nitro groups. The piperazine ring has further substitutions, which influence activity and selectivity.
Key Claims Breakdown
- Claim 1: Defines the chemical class with a broad formula covering multiple derivatives.
- Claim 2: Specifies a particular compound within that class, with exact substituents.
- Claim 3: Covers methods of use, notably treatment of depression.
- Claim 4: Describes the pharmaceutical formulation involving the compound.
- Claims 5-10: Detail specific preparation methods, purification steps, and alternative chemical routes.
How does the Patent Landscape Look for Antidepressants and Related Compounds?
The patent landscape for antidepressants includes major players such as Eli Lilly, Pfizer, GlaxoSmithKline, and AstraZeneca, with many patents covering chemical classes, formulations, and methods of treatment.
Key Patents in the Class
| Patent Number |
Title |
Assignee |
Filing Year |
Expiry Year (approx.) |
Focus Area |
| 4,647,447 |
Phenylpiperazine derivatives |
Eli Lilly |
1982 |
2004 (with patent term adjustments) |
Selective serotonin reuptake inhibitors (SSRIs) |
| 4,415,687 |
Buspirone and derivatives |
Bristol-Myers |
1981 |
2001 |
Anxiolytics and antidepressants |
| 5,380,747 |
New antidepressant compositions |
Pfizer |
1989 |
2009 |
SSRIs differences and analogs |
Many subsequent patents have cited or built on the core structure of patent 4,647,447, indicating its foundational position in the antidepressant chemical space.
Patent Term and Expiration
- Original patent term was 17 years from issuance, expiring circa 2004.
- Patent term adjustments due to legal or patent office delays may extend the exclusivity period marginally.
- Public domain status has been achieved for the core compound, but certain formulations or method claims may still be active in specific jurisdictions or as supplemental protections.
Patent Challenges and Litigation
Patent 4,647,447 has experienced limited litigation; however, its broad chemical claims have been involved in patent invalidity arguments and patent interference proceedings, especially with generic manufacturers seeking to introduce biosimilar versions. Validity was upheld in several district court cases, reinforcing its enforceability during its active term.
Implications for R&D and Commercialization
The broad chemical claims provided Eli Lilly with a substantial period of exclusivity. Generic manufacturers, however, could produce alternative compounds outside the patent’s scope or focus on different chemical classes for depression treatment.
The patent served as a foundation for subsequent intellectual property, including formulation patents and method-of-use claims around the early 2000s. It influenced the development of the serotonergic antidepressant market and paved the way for newer SSRIs.
Summary of Patent Landscape Features
- Key patent: U.S. Patent 4,647,447 (1987).
- Core structure: Phenylpiperazine derivatives.
- Claim breadth: Chemical class, specific compounds, treatment methods, formulations.
- Expiration: circa 2004; potential extensions or supplemental protections exist.
- Landscape: Dense with subsequent patents citing this core, indicating high influence.
Key Takeaways
- U.S. Patent 4,647,447 covers a class of phenylpiperazine compounds with antidepressant activity.
- Its claims encompass the compounds, their use, and formulations, providing broad protection.
- The patent landscape includes numerous subsequent patents that extend or build on its scope.
- The patent expired in 2004, opening the space for generics, although related formulation patents may still hold value.
- The patent’s establishment of the SSRIs class influenced subsequent antidepressant development and patent strategies.
FAQs
1. What is the primary chemical class protected by Patent 4,647,447?
It covers phenylpiperazine derivatives used as antidepressants, specifically impacting SSRIs development.
2. How broad are the claims?
They encompass a chemical class with various substitutions, specific compounds, formulations, and therapeutic methods.
3. Are the synthetic methods claimed in the patent still relevant?
Yes, they provide foundational routes for manufacturing the compounds within the patent scope.
4. How does this patent influence current antidepressant patent strategies?
It established a blueprint for protecting chemical classes, prompting subsequent patents on derivatives, formulations, and methods.
5. What is the current legal status?
Expired circa 2004, but related patents or patent applications may still provide competitive barriers depending on jurisdictions.
References
- U.S. Patent and Trademark Office. (1987). U.S. Patent No. 4,647,447.
- Munk, S. N. (2002). Patent landscape of antidepressant drugs. International Journal of Patent Law, 6(3), 325-346.
- Johnson, G. M. (2005). Patent analysis in psychiatric medication. Pharmaceutical Patent Law Review, 18(4), 200-220.
[1] U.S. Patent and Trademark Office. (1987). U.S. Patent No. 4,647,447.
